Irbesartan reducerede signifikant den relative risiko i det kombinerede primære endepunkt med fordobling af serum- kreatinin, slutstadium af nyresygdom (ESRD) eller totalmortalitet.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.